Most of medicine was built on men's bodies. According to TechCrunch, Evvy just raised $40 million to address that gap, one swab at a time.
Priyanka Jain's company, launched in 2021 alongside co-founders Laine Bruzek and Pita Navarro, announced the Series B funding led by Catalio Capital Management on Tuesday. The round signals momentum in women's health tech, and real money betting that precision medicine requires better female biological data.
Evvy's process is straightforward: users send in a vaginal swab, the lab runs it through mNGS sequencing, a clinician reviews it, and patients receive results with a diagnosis, clinical interpretation, and next steps. The company now serves over 100,000 patients and works with 3,000 practitioners across the US.
The real story is the dataset Jain is building. According to the TechCrunch report, Evvy has published 15 peer-reviewed papers, identified novel bacterial vaginosis subtypes, and discovered hundreds of previously uncatalogued vaginal microbiome genomes. This is infrastructure for precision medicine that includes women.
Jain's strategy involves deploying AI, specifically Evvy's AI assistant, EvvyAI (launched in May), to identify patterns across microbiome data, symptoms, hormones, and health outcomes that traditional medicine has missed for decades. You cannot train AI to understand women's health on datasets that never properly measured it.
The women's health startup ecosystem is growing rapidly, with ventures in fertility tracking and maternal care attracting capital. Evvy's approach differs. They are not just selling a service; they are aggregating biological ground truth. The dataset of 15 peer-reviewed publications' worth of novel microbiome genomes becomes more valuable each time a new clinician joins the platform.
The $40M Series B is a bet that patient data, AI, and clinical collaboration can deliver on precision medicine's promise to women. In a field where most medical assumptions excluded them, that matters.
